Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2019

01-08-2019 | Obesity | Research Article

Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients

Authors: Leonor Huete, Francisco Javier Manzano-Lista, Isabel Aránguez, Maria S. Fernández-Alfonso

Published in: International Journal of Clinical Pharmacy | Issue 4/2019

Login to get access

Abstract

Background Obesity is a risk factor for cardiovascular disease, the leading cause of death. Health education, nutritional follow-up, and life style habits modification are key for cardiovascular risk reduction in obese patients. Objective To measure the impact of pharmacist’s intervention on cardiovascular risk in obese patients. Setting A Spanish community pharmacy. Method Obese patients (BMI ≥ 30) with (group A, n = 30) and without (group B, n = 14) comorbidities were selected. Variables determined in first visit on-site: anthropometric values (weight, height, waist circumference), blood pressure, glycemic (glucose, HbA1c) and lipid parameters (total cholesterol, HDL-c, LDL-c, triglycerides). The PharmaFit Protocol consisted in a 24-month follow-up focusing (i) monthly on adherence to nutritional guidelines and modification of life style habits, and (ii) bi-monthly on anthropometric variables, blood pressure, and biochemical determinations. Feedback was provided to the primary care physician or specialist. Main ouitcome measure Cardiovascular risk estimated by REGICOR score. Results Anthropometric variables significantly decreased in all groups. Plasma glucose levels were significantly reduced in group A without changes in HbA1c. Lipid parameters significantly improved in group A, whereas HDL-c significantly raised in all groups. REGICOR score was significantly reduced in group A female (13.8 ± 1.6 vs. 5.8 ± 1, p < 0.0001) and male (12.7 ± 1.7 vs. 4.4. ± 0.6, p < 0.005) patients, and in group B female patients (3.5 ± 0.7 vs. 1.9 ± 0.4, p < 0.001). Conclusion Community pharmacist intervention, delivered as a 24-month follow-up and combining health and dietary education, has a highly positive impact on the reduction of cardiovascular risk in obese patients.
Literature
3.
go back to reference Nagai M, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Sone T, Hozawa A, Kawado M, Hashimoto S, Tsuji I. Impact of obesity, overweight and underweight on life expectancy and lifetime medical expenditures: The Ohsaki Cohort Study. BMJ Open. 2012;2(3):e000940.CrossRefPubMedPubMedCentral Nagai M, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Sone T, Hozawa A, Kawado M, Hashimoto S, Tsuji I. Impact of obesity, overweight and underweight on life expectancy and lifetime medical expenditures: The Ohsaki Cohort Study. BMJ Open. 2012;2(3):e000940.CrossRefPubMedPubMedCentral
4.
go back to reference The WHO Global Strategy on Diet. Physical activity and health. Geneva: World Health Organization; 2004. ISBN 92 4 159222 2. The WHO Global Strategy on Diet. Physical activity and health. Geneva: World Health Organization; 2004. ISBN 92 4 159222 2.
5.
go back to reference 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. World Health Organization, Geneva, (2008). ISBN: 9789241597418. 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. World Health Organization, Geneva, (2008). ISBN: 9789241597418.
7.
go back to reference Rotta I, Salgado TM, Silva ML, Correr CJ, Fernández-Limos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). Int J Clin Pharm. 2015;37(65):687–97.CrossRefPubMed Rotta I, Salgado TM, Silva ML, Correr CJ, Fernández-Limos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). Int J Clin Pharm. 2015;37(65):687–97.CrossRefPubMed
8.
go back to reference Ifeanyi Chizaro E, Evans M, van Woerden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. Value Health Reg Issues. 2015;7:9–21.CrossRef Ifeanyi Chizaro E, Evans M, van Woerden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. Value Health Reg Issues. 2015;7:9–21.CrossRef
9.
go back to reference O’Neal KS, Crosby KM. What is the role of the pharmacist in obesity management? Curr Obes Rep. 2014;3(3):298–306.CrossRefPubMed O’Neal KS, Crosby KM. What is the role of the pharmacist in obesity management? Curr Obes Rep. 2014;3(3):298–306.CrossRefPubMed
10.
go back to reference Naeem S. Role of pharmacists in obesity management. JPPCM. 2017;3(3):191–3.CrossRef Naeem S. Role of pharmacists in obesity management. JPPCM. 2017;3(3):191–3.CrossRef
11.
go back to reference Department of Health. Pharmacy in England. Building on strengths—delivering the future. London: HM Government; 2008. Department of Health. Pharmacy in England. Building on strengths—delivering the future. London: HM Government; 2008.
12.
go back to reference Toubro SDI, Hermansen I, Herborg H, Astrup AV. Dietary guidelines on obesity at Danish pharmacies. Results of a 12-week course with a 1-year follow-up. Ugeskr Laeger. 1999;161(38):5308–513.PubMed Toubro SDI, Hermansen I, Herborg H, Astrup AV. Dietary guidelines on obesity at Danish pharmacies. Results of a 12-week course with a 1-year follow-up. Ugeskr Laeger. 1999;161(38):5308–513.PubMed
13.
go back to reference National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: Commonwealth of Australia; 2003. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: Commonwealth of Australia; 2003.
14.
go back to reference Malone M, Alger-Mayer SA, Anderson DA. The lifestyle challenge program: a multidisciplinary approach to weight management. Ann Pharmacother. 2005;39(12):2015–20.CrossRefPubMed Malone M, Alger-Mayer SA, Anderson DA. The lifestyle challenge program: a multidisciplinary approach to weight management. Ann Pharmacother. 2005;39(12):2015–20.CrossRefPubMed
16.
go back to reference Declaración de la Profesión farmacéutica: Farmacia comunitaria. Consejo General de Colegios de Farmaceúticos, 2018. Declaración de la Profesión farmacéutica: Farmacia comunitaria. Consejo General de Colegios de Farmaceúticos, 2018.
19.
go back to reference European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769–818.CrossRef European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769–818.CrossRef
20.
go back to reference Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.CrossRefPubMedPubMedCentral Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.CrossRefPubMedPubMedCentral
21.
go back to reference Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253–61.CrossRefPubMed Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253–61.CrossRefPubMed
22.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRef
23.
go back to reference Um IS, Armour C, Krass I, Gill T, Chaar BB. Weight management in community pharmacy: what do the experts think? Int J Clin Pharm. 2013;35(3):447–54.CrossRefPubMed Um IS, Armour C, Krass I, Gill T, Chaar BB. Weight management in community pharmacy: what do the experts think? Int J Clin Pharm. 2013;35(3):447–54.CrossRefPubMed
24.
go back to reference Harmon M, Pogge E, Boomershine V. Evaluation of a pharmacist-led, 6-month weight loss program in obese patients. J Am Pharm Assoc. 2014;54(3):302–7.CrossRef Harmon M, Pogge E, Boomershine V. Evaluation of a pharmacist-led, 6-month weight loss program in obese patients. J Am Pharm Assoc. 2014;54(3):302–7.CrossRef
25.
go back to reference Gardner SF, Skelton DR, Rollins SD, Hastings JK. Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy. 1995;15(3):292–6.PubMed Gardner SF, Skelton DR, Rollins SD, Hastings JK. Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy. 1995;15(3):292–6.PubMed
26.
go back to reference Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162(10):1149–55.CrossRefPubMed Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162(10):1149–55.CrossRefPubMed
27.
go back to reference Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–53.CrossRefPubMed Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–53.CrossRefPubMed
28.
go back to reference Neto PR, Marusic S, de Lyra Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharm Sci. 2011;14(2):249–63.CrossRefPubMed Neto PR, Marusic S, de Lyra Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharm Sci. 2011;14(2):249–63.CrossRefPubMed
29.
go back to reference Domingues EA, Ferrit-Martín M, Calleja-Hernández MÁ. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy. Int J Clin Pharm. 2017;39(1):52–60.CrossRefPubMed Domingues EA, Ferrit-Martín M, Calleja-Hernández MÁ. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy. Int J Clin Pharm. 2017;39(1):52–60.CrossRefPubMed
30.
go back to reference Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006;9(4):202–8.CrossRefPubMed Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006;9(4):202–8.CrossRefPubMed
Metadata
Title
Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients
Authors
Leonor Huete
Francisco Javier Manzano-Lista
Isabel Aránguez
Maria S. Fernández-Alfonso
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2019
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00856-w

Other articles of this Issue 4/2019

International Journal of Clinical Pharmacy 4/2019 Go to the issue